5 Annual Report 2024 Review of Operations Research and Development Corporate Financial › New data presented on the effectiveness and utility of EXO-NET at the Australia and New Zealand Society for Extracellular Vesicles (ANSEV) conference › New data presented on high-throughput EXO-NET exosome isolation and biomarker discovery in breast and ovarian cancers at Promega hosted workshop at the Association for Molecular Pathology (AMP) annual meeting › Validation of NEURO-NET demonstrating isolation of brain-derived exosomes in Alzheimer’s Disease › Serum equivalence study confirmed EXO-NET isolates exosomes from both plasma and serum samples, enabling access to large ovarian cancer serum biobanks for further development of the EXO-OC test › In vitro proof-of-concept for breakthrough CAR-exosome therapy to target and kill breast cancer › Monitoring study demonstrated SubB2M-CA15-3 test detected key breast cancer subtypes, correctly identified 19% more breast cancers than a leading test and was effective for monitoring breast cancer › Analytical validation of SubB2M-CA125 test showing assay reproducibility and discrimination of both early and latestage ovarian cancers from healthy controls › Completed SubB2M-based SPR assay evaluation on Nicoya ALTO instrument for potential multi-cancer risk assessment test › David Williams, experienced director and investment banker, appointed Non-Executive Director and Chairman, bringing substantial financial, governance and corporate expertise › Successful capital raise with total funds raised of $9.4m via a placement to institutional and sophisticated investors ($7m) and SPP ($2.4m - received post year-end) › Cash of $9.2 million at 30 June 2024 to advance product development and commercial › Net loss of $6.6 million for the year ended 30 June 2024 › Research and Development Tax Refund of $1.02m recognised for the 2024 financial year $9.2m Cash Balance
RkJQdWJsaXNoZXIy MjE2NDg3